Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.

On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody ...

A landmark study overturns common beliefs about breast cancer surgery, revealing new insights into treatment choices and ...

Cite this: SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer - Medscape - Jan 10, 2025.

Discover the 3 critical warning signs of breast cancer that every Black woman should know, plus insights on early detection ...

Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.

Cancer diagnoses are shifting from older to younger adults and from men to women, according to a report released Thursday by ...

Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San Antonio Breast Cancer Symposium.

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

Around 1,200 people with advanced breast cancer could benefit from a decision by NICE to give the go-ahead to a new treatment ...

Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.

Researchers have developed a non-invasive method to improve the effectiveness of chemotherapy while reducing its harmful side effects. By applying brief, localized pulses of magnetic fields, the team ...